Dr. Sarah Winters

Medical Affairs Correspondent

Medical doctor turned healthcare journalist with 11 years of experience covering pharmaceutical developments, medical device innovation, and healthcare policy. Former emergency medicine physician who transitioned to journalism to bridge the gap between clinical practice and public health reporting. Specializes in drug approvals, clinical trial analysis, and the intersection of technology and patient care.

AI Author, more information here

Pfizer’s First‑Half 2026 Earnings Surge, Fueled by SSGJ‑707 Partnership Gains

Pfizer’s 1H 2026 results show strong earnings driven by milestone income from the SSGJ‑707 partnership, alongside growing oncology and obesity revenues, positioning the company for sustained growth.

Dr. Sarah Winters

21/08/2026, 19:21

3 minutes to read

Danaher Corp. Drives Healthcare Gains with Strong Earnings, Strategic Acquisitions

Danaher’s modest stock rise reflects strong earnings, strategic acquisitions and FDA‑cleared diagnostics, amid a healthcare sector buoyed by breakthrough drug and vaccine data.

Dr. Sarah Winters

20/08/2026, 19:19

3 minutes to read

How Bristol‑Myers Squibb’s Targeted Partnerships & Pipeline Focus Drive Strategic Growth

How Bristol‑Myers Squibb’s pipeline, strategic partnerships and regulatory focus shape its growth—insights on oncology, immune‑mediated diseases and smarter acquisitions.

Dr. Sarah Winters

20/08/2026, 15:46

3 minutes to read

Incite Corp Boosts Cell‑Therapy Pipeline with Long‑Term European Platform Deal

Incite Corp boosts its cell‑therapy pipeline with a long‑term partnership that secures advanced equipment, scales production, and accelerates clinical readiness.

Dr. Sarah Winters

20/08/2026, 13:55

3 minutes to read

Smith & Nebhew Launch Robotics Centre & New FLOW FLEXTEND Wand for Safer, Faster Orthopaedic Surgery

Smith & Nebhew plc launches a research centre with Imperial College London and the new FLOW FLEXTEND COBLATION Wand, advancing markerless surgical robotics and safer joint‑access procedures.

Dr. Sarah Winters

19/08/2026, 07:45

5 minutes to read

Sandoz & Henlius Expand Global Biosimilar Portfolio with 3 New Assets & Hyaluronidase Option

Explore Sandoz’s landmark collaboration with Shanghai Henlius Biotech, expanding its global biosimilar portfolio to 10 assets, boosting access and cost‑efficiency worldwide.

Dr. Sarah Winters

19/08/2026, 00:11

3 minutes to read

Amgen’s 2023 Surge: Strong Earnings, 4.1% Dividend, & Pipeline Growth

Amgen Inc.: A stable biotech stock with rising earnings, a 4.1% dividend, and a diversified pipeline—ideal for income‑focused investors seeking long‑term growth.

Dr. Sarah Winters

18/08/2026, 19:39

3 minutes to read

How Natera’s ctDNA Growth & AI Investments Propel Liquid Biopsy Leadership in 2025-26

Explore how Natera’s modest revenue growth, MRD acquisition, and AI‑driven digital pathology are driving the next wave of liquid biopsy diagnostics in oncology.

Dr. Sarah Winters

18/08/2026, 15:56

4 minutes to read

Johnson & Johnson Files 15,000-Share Sale by Officer Jennifer Taubert – SEC Rule 144 Compliance

Johnson & Johnson files Form 144: 15,000 shares sold by officer Jennifer Taubert – a routine insider sale that meets Rule 144, little market impact, but key for investors tracking corporate governance.

Dr. Sarah Winters

18/08/2026, 09:52

3 minutes to read

Insmed Q2 2026: Brinsupri Surges, Earnings Improve, and Clinical Gains Drive Higher Revenue Forecasts

Insmed’s Q2 2026 earnings beat expectations thanks to Brinsupri’s strong sales, and its clinical data shows robust PAH benefits and promising TPIP results, boosting future growth forecasts.

Dr. Sarah Winters

17/08/2026, 10:03

3 minutes to read

Older articles